APA (7th ed.) Citation

N, T., MP, S., S, N., T, P., C, F., L, C., . . . RV, F. (2009). Combined thiazolidinedione-metformin treatment synergistically improves insulin signalling to insulin receptor substrate-1-dependent phosphatidylinositol 3-kinase, atypical protein kinase C and protein kinase B/Akt in human diabetic muscle. Diabetologia, 52(1), 60. https://doi.org/10.1007/s00125-008-1180-z

Chicago Style (17th ed.) Citation

N, Temofonte, Sajan MP, Nimal S, Pastoor T, Fumero C, Casaubon L, Powe JL, Standaert ML, and Farese RV. "Combined Thiazolidinedione-metformin Treatment Synergistically Improves Insulin Signalling to Insulin Receptor Substrate-1-dependent Phosphatidylinositol 3-kinase, Atypical Protein Kinase C and Protein Kinase B/Akt in Human Diabetic Muscle." Diabetologia 52, no. 1 (2009): 60. https://doi.org/10.1007/s00125-008-1180-z.

MLA (9th ed.) Citation

N, Temofonte, et al. "Combined Thiazolidinedione-metformin Treatment Synergistically Improves Insulin Signalling to Insulin Receptor Substrate-1-dependent Phosphatidylinositol 3-kinase, Atypical Protein Kinase C and Protein Kinase B/Akt in Human Diabetic Muscle." Diabetologia, vol. 52, no. 1, 2009, p. 60, https://doi.org/10.1007/s00125-008-1180-z.